Mechanism of action of LAVA-051, a bispecific Vγ9Vδ2 T-cell engager, confirmed in the clinical setting November 10, 2022November 14, 2022 Submitted for presentation at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting